- Home
- GSHD vs LBRX Comparison
GSHD vs LBRX Comparison
Compare GSHD & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GSHD | LBRX |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | United States | United States |
| Employees | N/A | 27 |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 986.6M | 958.7M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | GSHD | LBRX |
|---|---|---|
| Price | $54.70 | $31.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 5 |
| Target Price | ★ $72.50 | $46.60 |
| AVG Volume (30 Days) | ★ 624.1K | 351.9K |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.04 | N/A |
| Revenue | ★ $365,304,000.00 | N/A |
| Revenue This Year | $16.40 | N/A |
| Revenue Next Year | $18.53 | N/A |
| P/E Ratio | $53.03 | ★ N/A |
| Revenue Growth | ★ 16.15 | N/A |
| 52 Week Low | $33.68 | $13.40 |
| 52 Week High | $103.85 | $35.35 |
Technical Indicators
Market Signals| Indicator | GSHD | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 62.30 | 49.89 |
| Support Level | $40.71 | $26.75 |
| Resistance Level | $56.00 | $34.10 |
| Average True Range (ATR) | 3.12 | 1.98 |
| MACD | 0.07 | -0.30 |
| Stochastic Oscillator | 70.50 | 34.42 |
Price Performance
Historical ComparisonAbout GSHD Goosehead Insurance Inc.
Goosehead Insurance Inc operates as an insurance agency. Its insurance products consist of homeowner's insurance; auto insurance; other personal lines products including flood, wind and earthquake insurance; excess liability or umbrella insurance; specialty lines insurance (motorcycle, recreational vehicle and other insurance); commercial lines insurance (general liability, property, and auto insurance for small businesses); and life insurance. Geographically, it operates in Texas, California, Illinois, Florida, and other regions. The company is has a single reportable segment: insurance distribution.
About LBRX LB Pharmaceuticals Inc
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.